MA44067A - Anticorps dirigés contre la quétiapine et utilisation associée - Google Patents

Anticorps dirigés contre la quétiapine et utilisation associée

Info

Publication number
MA44067A
MA44067A MA044067A MA44067A MA44067A MA 44067 A MA44067 A MA 44067A MA 044067 A MA044067 A MA 044067A MA 44067 A MA44067 A MA 44067A MA 44067 A MA44067 A MA 44067A
Authority
MA
Morocco
Prior art keywords
quetiapine
directed against
antibodies directed
associated use
antibodies
Prior art date
Application number
MA044067A
Other languages
English (en)
Inventor
Linda Colt
Thomas R Decory
Matthew G Donahue
Yong Gong
Eric Hryhorenko
Bart M Remmerie
Rhys Salter
Banumathi Sankaran
Theresa Tubbs
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA44067A publication Critical patent/MA44067A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9466—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA044067A 2015-12-17 2016-12-15 Anticorps dirigés contre la quétiapine et utilisation associée MA44067A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562268924P 2015-12-17 2015-12-17

Publications (1)

Publication Number Publication Date
MA44067A true MA44067A (fr) 2018-10-24

Family

ID=57799801

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044067A MA44067A (fr) 2015-12-17 2016-12-15 Anticorps dirigés contre la quétiapine et utilisation associée

Country Status (8)

Country Link
US (2) US10435478B2 (fr)
EP (1) EP3390455A1 (fr)
JP (1) JP6994461B2 (fr)
CN (1) CN108368180B (fr)
AU (1) AU2016370853A1 (fr)
CA (1) CA3008812A1 (fr)
MA (1) MA44067A (fr)
WO (1) WO2017106508A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014031645A1 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Anticorps dirigés contre des haptènes de rispéridone et leur utilisation
US20140057303A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Olanzapine Haptens and Use Thereof
PL3663317T3 (pl) * 2012-08-21 2023-06-05 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL3333195T3 (pl) * 2012-08-21 2021-02-22 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
WO2017106508A1 (fr) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Anticorps dirigés contre la quétiapine et utilisation associée
AU2016372069A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
CN116354904B (zh) * 2023-04-26 2023-08-01 北京丹大生物技术有限公司 一种喹硫平衍生物半抗原、抗原、抗喹硫平抗体及其应用
CN119505006A (zh) * 2024-11-14 2025-02-25 杭州旭科生物技术有限公司 抗喹硫平的抗体或其抗原结合片段及其应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ES2150428T3 (es) 1987-04-27 2000-12-01 Unilever Nv Ensayos de union especifica.
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU668159B2 (en) 1992-05-29 1996-04-26 Lilly Industries Limited Pharmaceutical compounds
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
DE69535855D1 (de) 1994-06-10 2008-11-20 Oklahoma Med Res Found Calciumbindende rekombinante antikörper gegen protein c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
WO1998059233A1 (fr) 1997-06-23 1998-12-30 Luminex Corporation Lasers entrelaces pour une mesure de fluorescences multiples
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
DE60334364D1 (de) 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2003082877A1 (fr) 2002-03-28 2003-10-09 Eli Lilly And Company Aryles benzodiazepines a substitution de piperazine et leur utilisation en tant qu'antagonistes de recepteur de dopamine dans le traitement de troubles psychotiques
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
US20040127489A1 (en) 2002-07-29 2004-07-01 David Pickar Novel antipsychotic combination therapies and compositions useful therein
DK1546134T3 (da) 2002-08-05 2007-09-10 Lilly Co Eli Piperazinsubstituerede arylbenzodiazepiner
KR101351122B1 (ko) 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
PL1658277T3 (pl) 2003-08-18 2012-10-31 H Lundbeck As Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
WO2005028458A1 (fr) 2003-09-23 2005-03-31 Fermion Oy Procede de preparation de quetiapine
AU2004278414B2 (en) 2003-10-01 2012-05-24 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
BRPI0415531B8 (pt) 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
EP1706743B1 (fr) 2003-12-12 2009-11-18 Inverness Medical Switzerland GmbH Essai
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
WO2005103250A1 (fr) 2004-04-26 2005-11-03 Takami Matsuyama MÉDICAMENT THÉRAPEUTIQUE CONTENANT UN ANTICORPS MONOCLONAL ANTI RÉCEPTEUR BÉTA DE FOLATE (FR-β)
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
FR2878850B1 (fr) 2004-12-02 2008-10-31 Cis Bio Internat Sa Derives de l'inositol-1-phosphate
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE0501418L (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
EP2077860B1 (fr) 2006-10-25 2014-04-09 Ramot at Tel-Aviv University Ltd Agents psychotropes présentant une activité sur les récepteurs nmda du glutamate
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
ES2405364T3 (es) 2006-12-29 2013-05-30 Abbott Laboratories Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
CN101091700B (zh) 2007-07-03 2011-06-08 上海现代药物制剂工程研究中心有限公司 富马酸喹硫平缓控释制剂组合物及其制备用途
CA2699062A1 (fr) 2007-09-27 2009-04-02 Novartis Ag Test de pharmacovigilance
EP3338795A1 (fr) 2008-07-21 2018-06-27 Probiodrug AG Dosage d'anticorps de diagnostic
AU2009279372A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
AU2009305203B2 (en) 2008-10-14 2013-03-07 Entasis Therapeutics Limited Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
WO2010096117A2 (fr) 2008-10-29 2010-08-26 Janssen Pharmaceutica Nv Procédés de traitement d’une psychose et de la schizophrénie basés sur des polymorphismes du gène erbb4
EP2194048A1 (fr) 2008-12-02 2010-06-09 Dirk Sartor Esters de nitrate pour le traitement de maladies vasculaires et métaboliques
AU2010206376B2 (en) 2009-01-26 2012-10-18 Egalet Ltd. Controlled release formulations with continuous efficacy
EP2406288B1 (fr) 2009-03-10 2016-12-14 Baylor Research Institute Vaccins ciblés vers des cellules présentant des antigènes
CA2927380C (fr) 2009-12-31 2017-07-04 Kempharm, Inc. Conjugues d'acides amines de quetiapine, procede de fabrication et d'utilisation de ceux-ci
WO2011112657A1 (fr) 2010-03-11 2011-09-15 Kempharm, Inc. Conjugués d'acides gras et de quétiapine, leur procédé de fabrication et leur utilisation
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2011159537A2 (fr) 2010-06-15 2011-12-22 The Regents Of The University Of California Procédé et dispositif pour la détection d'analytes
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
WO2012003418A2 (fr) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Ligands fonctionnellement sélectifs des récepteurs d2 de dopamine
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
WO2013088255A1 (fr) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Promédicaments de composés amine secondaires
BR112015003393A2 (pt) 2012-08-16 2017-07-04 Janssen Pharmaceutica Nv pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n
US20140057303A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Olanzapine Haptens and Use Thereof
CA2882489A1 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre des haptenes de paliperidone et leur utilisation
JP6216926B2 (ja) 2012-08-21 2017-10-25 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンに対する抗体及びその使用
EP2888263B1 (fr) 2012-08-21 2018-05-09 Janssen Pharmaceutica NV Haptènes de rispéridone et de palipéridone
WO2014031645A1 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Anticorps dirigés contre des haptènes de rispéridone et leur utilisation
CA2882454C (fr) 2012-08-21 2020-08-11 Matthew Garrett DONAHUE Haptenes de l'olanzipine
PL3663317T3 (pl) * 2012-08-21 2023-06-05 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
PL3321254T3 (pl) 2012-08-21 2021-01-11 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
PT3462173T (pt) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilização dos mesmos
CN110054694B (zh) 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
PL3333195T3 (pl) * 2012-08-21 2021-02-22 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
EP3305784B1 (fr) 2012-08-21 2020-08-12 Janssen Pharmaceutica NV Haptènes de quétiapine à utiliser dans des dosages immunologiques
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017106508A1 (fr) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Anticorps dirigés contre la quétiapine et utilisation associée
AU2016372069A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to risperidone and use thereof

Also Published As

Publication number Publication date
US20170176474A1 (en) 2017-06-22
WO2017106508A1 (fr) 2017-06-22
CN108368180A (zh) 2018-08-03
US10435478B2 (en) 2019-10-08
CN108368180B (zh) 2022-07-26
JP6994461B2 (ja) 2022-02-04
AU2016370853A1 (en) 2018-06-07
EP3390455A1 (fr) 2018-10-24
CA3008812A1 (fr) 2017-06-22
US20200002438A1 (en) 2020-01-02
US11104742B2 (en) 2021-08-31
JP2019504014A (ja) 2019-02-14

Similar Documents

Publication Publication Date Title
MA49823A (fr) Anticorps dirigés contre pd-l1
EP3333192A4 (fr) Anticorps dirigé contre le glypican-3 et application associée
EP3354661A4 (fr) Anticorps entièrement humain contre cd137 humain et son utilisation
IL255011A0 (en) Modified gamma delta cells and uses thereof
DK3177259T3 (da) Forbindelses- og beholdersystem
EP3334757A4 (fr) Anticorps anti-tigit
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
PL3653221T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
PL3280441T3 (pl) Przeciwciała przeciwko sortilinie i sposoby ich stosowania
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
IL257170B (en) Stable proteins and methods for designing same
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
EP2933121A4 (fr) Clou et bandage pneumatique
DK3377634T3 (da) Bakteriebaseret proteinafgivelse
EP3372594A4 (fr) Dérivé pyrimidine et son utilisation
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
EP3310319C0 (fr) Système de raccordement et de contenant
HUE050820T2 (hu) Moduláris energiatároló eljárás és rendszer
EP3350489A4 (fr) Soupape et raccord
EP3683236A4 (fr) Anticorps dirigé contre dlk1 humain et utilisation associée
IL259202A (en) Modified immune cells and uses thereof
SI3672948T1 (sl) Piridinamin-piridon in spojine pirimidinamin-piridona
PL3331063T3 (pl) Akumulator i zespół akumulatorowy